摘要
目的 探讨口服调释类仿制药研发中乙醇诱导的剂量倾泻研究要求。方法 结合审评实际情况,对口服调释类仿制药乙醇诱导的剂量倾泻研究中常见问题进行了分析,总结了国内外药品监管机构相关的技术要求,提出了研究建议。结果与结论 乙醇可能会改变调释制剂药物释放特性,带来用药安全性和有效性问题。建议口服调释类仿制药研发时予以关注,并进行相应的体外研究,以评价制剂在体内乙醇环境中出现药物突释(剂量倾泻)的可能性。
Abstract
OBJECTIVE To discuss the the requirements of alcohol-induced dose dumping in the development of generic oral modified-release preparations. METHODS Based on the review, the common problems on alcohol-induced dose dumping in the development of generic oral modified-release preparations were analyzed, the recommendations on dose dumping of domestic and foreign drug regulatory authorities were summarized, and general considerations were put forward. RESULTS AND CONCLUSION Alcohol may alter the release characteristics of modified-release preparations and cause safety and effectiveness problems. In vitro studies are recommended to evaluate the possibility of sudden drug release (dose dumping) in the presence of alcohol in vivo.
关键词
调释制剂 /
乙醇诱导 /
剂量倾泻 /
药物研发 /
关键质量属性 /
体外评价
{{custom_keyword}} /
Key words
modified-release preparations /
alcohol-induced /
dose dumping /
drug development /
critical quality attribute /
in vitro evaluation
{{custom_keyword}} /
魏赫, 李雪梅.
口服调释类仿制药乙醇诱导的剂量倾泻研究探讨[J]. 中国药学杂志, 2022, 57(3): 209-213 https://doi.org/10.11669/cpj.2022.03.007
WEI He, LI Xue-mei.
Discussion on Alcohol-induced Dose Dumping in the Development of Generic Oral Modified-Release Preparations[J]. Chinese Pharmaceutical Journal, 2022, 57(3): 209-213 https://doi.org/10.11669/cpj.2022.03.007
中图分类号：
R944
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] European Medicines Agency(EMA). Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms[EB/OL]. 2015 [2021-05-20]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmacokinetic-clinical-evaluation-modified-release-dosage-forms_en. pdf
[2] Food and Drug Administration (FDA). Information for Healthcare Professionals: Hydromorphone Hydrochloride Extended-Release Capsules (marketed as Palladone) [EB/OL]. 2005-07 [2021-05-18]. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-healthcare-professionals-hydromorphone-hydro chloride-extended-release-capsules-marketed
[3] European Medicines Agency(EMA). European Medicines Agency concludes review of modified-release oral opioids of the WHO level Ⅲ scale for the management of pain[EB/OL]. 2011-04-20 [2021-02-10]. https://www.ema.europa.eu/en/documents/referral/assessment-report-authorised-modified-release-oral-medicinal-products-who-level-iii-scale-management_en. pdf
[4] European Medicines Agency (EMA). Questions and answers on Ethirfin and associated names (morphine sulphate, prolonged-release capsules, 20, 60, 120 and 200 mg)[EB/OL]. 2010-07-23 [2021-05-07]. https://www.ema.europa.eu/en/medicines/human/referrals/ethirfin
[5] Food and Drug Administration (FDA). Bioavailability Studies Submitted in NDAs or INDs — General Considerations[EB/OL]. 2019-02 [2021-02-10]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bi oavailability-studies-submitted-ndas-or-inds-general-considerations
[6] Food and Drug Administration (FDA). Product-Specific Guidances for Generic Drug Development [EB/OL]. [2021-09-10]. https://www.fda.gov/drugs/guidances-drugs/product-specific-guidances-generic-drug-development
[7] Food and Drug Administration (FDA). ANDA-Submissions-Refuse-to-Receive-Standards-Rev. 2[EB/OL]. 2016-12 [2021-02-10]. https://www.fda.gov/media/86660/download
[8] Food and Drug Administration (FDA). ANDA Submissions-Amendments to Abbreviated New Drug Applications Under GDUFA[EB/OL]. 2017-10 [2021-05-11]. https://www.fda.gov/media/89258/download
[9] European Medicines Agency (EMA). Guideline on the clinical development of medicinal products intended for the treatment of pain[EB/OL]. 2017-07-01 [2021-02-10]. https://www.ema.europa.eu/en/clinical-development-medicinal-products-intended-treatment-pain
[10] European Medicines Agency (EMA). Quality of medicines questions and answers: Part 2[EB/OL]. [2021-05-11]. https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/qa-quality/quality-medicines-questions-answers-part-2#specific-types-of-product----need-for-in-vitro-dissolution-studies-with-alcohol-for-modified-release-oral-products-in cluding-opioid-drug-products-section
[11] World Health Organization(WHO). TRS 970 Annex 3 Pharmaceutical development of multisource (generic) finished pharmaceutical products - points to consider[EB/OL]. 2012-06 [2021-05-11]. https://www.who.int/medicines/areas/quality_safety/quality_assurance/expert_committee/trs_970/en/
[12] National Medical Products Administration (NMPA). Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA [EB/OL]. 2016 [2021-05-11]. https://www.nmpa.gov.cn/zhuanti/ypqxgg/ggzhcfg/20160318210001633.html
[13] Food and Drug Administration (FDA). Quality by Design for ANDAs:An Example forModified Release Dosage Forms[EB/OL]. 2012 [2021-05-11]. https://www.fda.gov/media/83664/download
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(990 KB)
